CALHM1 P86L polymorphism does not alter amyloid-β or tau in cerebrospinal fluid

Neuroscience Letters

Volumn 469, Issue 2, 2010, Pages 265-267

  Giedraitis, Vilmantas ^a   Glaser, Anna ^a   Sarajärvi, Timo ^b   Brundin, RoseMarie ^a   Gunnarsson, Malin Degerman ^a   Schjeide, Brit Maren ^c,d   Tanzi, Rudolph E ^d   Helisalmi, Seppo ^b   Pirttilä, Tuula ^b   Kilander, Lena ^a   Lannfelt, Lars ^a   Soininen, Hilkka ^b   Bertram, Lars ^c,d   Ingelsson, Martin ^a   Hiltunen, Mikko ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Biomarker; Calcium homeostasis modulator 1; CALHM1; Cerebrospinal fluid; Genotyping SNP; Phospho tau; Total tau

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM HOMEOSTASIS MODULATOR 1; MEMBRANE PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL CULTURE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN POLYMORPHISM;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CALCIUM CHANNELS; COGNITION DISORDERS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FINLAND; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; SWEDEN; TAU PROTEINS;

EID: 73049085201     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.12.011     Document Type: Article

References (12)

1. Bertram L., McQueen M.B., Mullin K., Blacker D., and Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Genetics 39 (2007) 17-23
2. Bertram L., Schjeide B.M., Hooli B., Mullin K., Hiltunen M., Soininen H., Ingelsson M., Lannfelt L., Blacker D., and Tanzi R.E. No association between CALHM1 and Alzheimer's disease risk. Cell 135 (2008) 993-994 (author reply 994-996)
3. Dreses-Werringloer U., Lambert J., Vingtdeux V., Zhao H., Vais H., Siebert A., Jain A., Koppel J., Rovelet-Lecrux A., Hannequin D., Pasquier F., Galimberti D., Scarpini E., Mann D., Lendon C., Campion D., Amouyel P., Davies P., Foskett J., Campagne F., and Marambaud P. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 133 (2008) 1149-1161
4. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., and Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Archives of Neurology 55 (1998) 937-945
5. Johansson A., Katzov H., Zetterberg H., Feuk L., Johansson B., Bogdanovic N., Andreasen N., Lenhard B., Brookes A., Pedersen N., Blennow K., and Prince J. Variants of CYP46A1 may interact with age and APOE to influence Aß42 levels in Alzheimer's disease. Human Genetics 114 (2004) 581-587
6. Kemppainen N.M., Aalto S., Wilson I.A., Nagren K., Helin S., Bruck A., Oikonen V., Kailajarvi M., Scheinin M., Viitanen M., Parkkola R., and Rinne J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68 (2007) 1603-1606
7. McKhann G., Drachman D., and Folstein M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of department of health and human services task forces on Alzheimer's disease. Neurology 34 (1984) 939-944
8. Minster R.L., Demirci F.Y., DeKosky S.T., and Kamboh M.I. No association between CALHM1 variation and risk of Alzheimer disease. Human Mutation 30 (2009) E566-E569
9. Sleegers K., Brouwers N., Bettens K., Engelborghs S., van Miegroet H., De Deyn P.P., and Van Broeckhoven C. No association between CALHM1 and risk for Alzheimer dementia in a Belgian population. Human Mutation 30 (2009) E570-E574
10. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 1977-1981
11. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., Csako G., Levy J.A., Bartko J.J., and Cohen R.M. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biological Psychiatry 56 (2004) 670-676
12. Tapiola T., Pirttila T., Mehta P.D., Alafuzofff I., Lehtovirta M., and Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiology of Aging 21 (2000) 735-740